UroGen Pharma URGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $50.96M+152% | $37.84M+54.0% | $27.48M+9.0% | $24.22M+10.8% | $20.25M+7.8% | ||
| -$23.57M+46.2% | -$26.36M+29.7% | -$33.35M-40.9% | -$49.94M-49.5% | -$43.84M-35.8% | ||
| -46.3%+170pp | -69.7%+83.0pp | -121.3%-27.4pp | -206.2%-53.3pp | -216.5%-44.6pp | ||
| $50.96M+152% | $37.84M+54.0% | $27.48M+9.0% | $24.22M+10.8% | $20.25M+7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- Gross margin is 89.7% and operating margin is -329.7%, with a -94.8% net margin.
- Where does UroGen Pharma's income statement data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.